SEC 13F Intelligence

Rhenman & Partners Asset Management AB / REGN

Rhenman & Partners Asset Management AB’s Regeneron Pharmaceuticals Position

Does Rhenman & Partners Asset Management AB own Regeneron Pharmaceuticals (REGN)? Yes — 48.1K shares worth $37M (+4.59% of its 13F portfolio) as of Q1 2026, down from 61.4K shares the prior filed quarter.

Position Value
$37M
Q1 2026
Shares
48.1K
% of Portfolio
+4.59%
Quarters Held
27
currently held

Position History REGN

Reported value by quarter
Q4 ’18: $6MQ4 ’18Q1 ’19: $7MQ2 ’19: $14MQ3 ’19: $12MQ4 ’19: $10MQ4 ’19Q2 ’20: $8MQ3 ’20: $13MQ4 ’20: $19MQ1 ’21: $9MQ1 ’21Q2 ’21: $14MQ1 ’22: $20MQ2 ’22: $8MQ3 ’22: $24MQ3 ’22Q4 ’22: $27MQ1 ’23: $29MQ2 ’23: $25MQ3 ’23: $33MQ3 ’23Q4 ’23: $34MQ1 ’24: $33MQ2 ’24: $34MQ3 ’24: $41MQ3 ’24Q4 ’24: $31MQ1 ’25: $20MQ2 ’25: $15MQ3 ’25: $20MQ3 ’25Q4 ’25: $47MQ1 ’26: $37Mfilingsflow.com
QuarterSharesValue% of Portfolio
Q1 202648.1K$37M+4.59%
Q4 202561.4K$47M+4.43%
Q3 202536.1K$20M+2.25%
Q2 202527.7K$15M+1.84%
Q1 202531.8K$20M+2.31%
Q4 202443.5K$31M+3.18%
Q3 202439.0K$41M+3.33%
Q2 202432.0K$34M+3.23%
Q1 202434.3K$33M+3.13%
Q4 202339.0K$34M+3.42%
Q3 202340.0K$33M+3.55%
Q2 202335.0K$25M+2.65%
Q1 202335.5K$29M+3.16%
Q4 202237.0K$27M+2.79%
Q3 202232.0K$24M+2.51%
Q2 202214.0K$8M+0.94%
Q1 202228.5K$20M+1.96%
Q2 202125.0K$14M+0.95%
Q1 202120.0K$9M+0.66%
Q4 202040.0K$19M+1.58%
Q3 202022.5K$13M+1.12%
Q2 202012.5K$8M+0.84%
Q4 201927.0K$10M+1.11%
Q3 201945.0K$12M+1.57%
Q2 201945.0K$14M+1.55%
Q1 201916.0K$7M+0.77%
Q4 201817.0K$6M+0.73%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Rhenman & Partners Asset Management AB’s full portfolio or all institutional holders of REGN.